Madelon C Vonk

List of Publications by Year
in descending order

155 papers	10,388 citations	101543 36 h-index	33894 99 g-index
160 all docs	160 docs citations	160 times ranked	9306 citing authors

#	Article	IF	Citations
1	2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Arthritis and Rheumatism, 2013, 65, 2737-2747.	6.7	2,359
2	2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2013, 72, 1747-1755.	0.9	1,705
3	Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Annals of the Rheumatic Diseases, 2010, 69, 1809-1815.	0.9	1,017
4	Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Annals of the Rheumatic Diseases, 2014, 73, 1340-1349.	0.9	633
5	Autologous Hematopoietic Stem Cell Transplantation vs Intravenous Pulse Cyclophosphamide in Diffuse Cutaneous Systemic Sclerosis. JAMA - Journal of the American Medical Association, 2014, 311, 2490.	7.4	566
6	Proteome-wide Analysis and CXCL4 as a Biomarker in Systemic Sclerosis. New England Journal of Medicine, 2014, 370, 433-443.	27.0	365
7	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. Nature Genetics, 2010, 42, 426-429.	21.4	351
8	Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis. Autoimmunity Reviews, 2020, 19, 102458.	5.8	231
9	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. PLoS Genetics, 2011, 7, e1002178.	3.5	201
10	The STAT4 gene influences the genetic predisposition to systemic sclerosis phenotype. Human Molecular Genetics, 2009, 18, 2071-2077.	2.9	163
11	The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Annals of the Rheumatic Diseases, 2016, 75, 1567-1573.	0.9	126
12	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	10.7	118
13	Treatment outcome in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study (ESOS). Annals of the Rheumatic Diseases, 2017, 76, 1207-1218.	0.9	107
14	A systemic sclerosis and systemic lupus erythematosus pan-meta-GWAS reveals new shared susceptibility loci. Human Molecular Genetics, 2013, 22, 4021-4029.	2.9	104
15	Unraveling SSc Pathophysiology; The Myofibroblast. Frontiers in Immunology, 2018, 9, 2452.	4.8	103
16	Identification of CSK as a systemic sclerosis genetic risk factor through Genome Wide Association Study follow-up. Human Molecular Genetics, 2012, 21, 2825-2835.	2.9	98
17	Rituximab treatment in patients with refractory inflammatory myopathies. Rheumatology, 2011, 50, 2206-2213.	1.9	88
18	Fast track algorithm: How to differentiate a â€œscleroderma patternâ€•from a â€œnon-scleroderma patternâ€• Autoimmunity Reviews, 2019, 18, 102394.	5.8	79

#	Article	IF	Citations
19	Analysis of the influence of PTPN22 gene polymorphisms in systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 454-462.	0.9	75
20	A GWAS follow-up study reveals the association of the IL12RB2 gene with systemic sclerosis in Caucasian populations. Human Molecular Genetics, 2012, 21, 926-933.	2.9	74
21	A replication study confirms the association of TNFSF4 (OX40L) polymorphisms with systemic sclerosis in a large European cohort. Annals of the Rheumatic Diseases, 2011, 70, 638-641.	0.9	63
22	Confirmation ofTNIP1but notRHOBandPSORS1C1as systemic sclerosis risk factors in a large independent replication study. Annals of the Rheumatic Diseases, 2013, 72, 602-607.	0.9	56
23	Disease-related and psychosocial factors associated with depressive symptoms in patients with systemic sclerosis, including fear of progression and appearance self-esteem. Journal of Psychosomatic Research, 2012, 72, 199-204.	2.6	54
24	Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study. Rheumatology, 2018, 57, 370-381.	1.9	53
25	New insight on the Xq28 association with systemic sclerosis. Annals of the Rheumatic Diseases, 2013, 72, 2032-2038.	0.9	52
26	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. Journal of Clinical Epidemiology, 2014, 67, 706-714.	5.0	52
27	Patterns and predictors of skin score change in early diffuse systemic sclerosis from the European Scleroderma Observational Study. Annals of the Rheumatic Diseases, 2018, 77, 563-570.	0.9	50
28	The TRAF1-C5 region on chromosome 9q33 is associated with multiple autoimmune diseases. Annals of the Rheumatic Diseases, 2010, 69, 696-699.	0.9	49
29	Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise. Arthritis Care and Research, 2012, 64, 351-357.	3.4	49
30	Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Crossâ€Disease Metaâ€Analysis of Genomeâ€Wide Association Studies. Arthritis and Rheumatology, 2016, 68, 2338-2344.	5.6	46
31	Scleroderma-polymyositis overlap syndrome versus idiopathic polymyositis and systemic sclerosis: a descriptive study on clinical features and myopathology. Arthritis Research and Therapy, 2014, 16, R111.	3.5	45
32	Development of a five-year mortality model in systemic sclerosis patients by different analytical approaches. Clinical and Experimental Rheumatology, 2010, 28, S18-27.	0.8	45
33	Borderline pulmonary arterial pressure in systemic sclerosis patients: a post-hoc analysis of the DETECT study. Arthritis Research and Therapy, 2014, 16, 493.	3.5	44
34	Platelet-derived growth factor receptor-Î² and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: a case-control study. Arthritis Research and Therapy, 2011, 13, R61.	3.5	41
35	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis and Rheumatology, 2019, 71, 964-971.	5.6	41
36	The Systemic Lupus Erythematosus IRF5 Risk Haplotype Is Associated with Systemic Sclerosis. PLoS ONE, 2013, 8, e54419.	2.5	38

#	Article	IF	Citations
37	A genome-wide association study follow-up suggests a possible role for PPARG in systemic sclerosis susceptibility. Arthritis Research and Therapy, 2014, 16, R6.	3.5	37
38	Skewed X chromosomal inactivation impacts T regulatory cell function in systemic sclerosis. Annals of the Rheumatic Diseases, 2010, 69, 2213-2216.	0.9	36
39	Influence of the IL6 Gene in Susceptibility to Systemic Sclerosis. Journal of Rheumatology, 2012, 39, 2294-2302.	2.0	34
40	Validity of the Fear of Progression Questionnaireâ€Short Form in patients with systemic sclerosis. Arthritis Care and Research, 2012, 64, 930-934.	3.4	34
41	Survival and organ involvement in patients with limited cutaneous systemic sclerosis and anti-topoisomerase-I antibodies: determined by skin subtype or auto-antibody subtype? A long-term follow-up study. Rheumatology, 2016, 55, 2001-2008.	1.9	34
42	A multicenter study confirms CD226 gene association with systemic sclerosis-related pulmonary fibrosis. Arthritis Research and Therapy, 2012, 14, R85.	3.5	32
43	Predictive factors for treatment-related mortality and major adverse events after autologous haematopoietic stem cell transplantation for systemic sclerosis: results of a long-term follow-up multicentre study. Annals of the Rheumatic Diseases, 2020, 79, 1084-1089.	0.9	32
44	Implication of IL-2/IL-21 region in systemic sclerosis genetic susceptibility. Annals of the Rheumatic Diseases, 2013, 72, 1233-1238.	0.9	30
45	Increased fascial thickness of the deltoid muscle in dermatomyositis and polymyositis: An ultrasound study. Muscle and Nerve, 2015, 52, 534-539.	2.2	30
46	Low heme oxygenase-1 levels in patients with systemic sclerosis are associated with an altered Toll-like receptor response: another role for CXCL4?. Rheumatology, 2016, 55, 2066-2073.	1.9	28
47	There is a need for new systemic sclerosis subset criteria. A content analytic approach. Scandinavian Journal of Rheumatology, 2018, 47, 62-70.	1.1	28
48	Pulmonary hypertension in connective tissue diseases, new evidence and challenges. European Journal of Clinical Investigation, 2021, 51, e13453.	3.4	28
49	Confirmation of association of the macrophage migration inhibitory factor gene with systemic sclerosis in a large European population. Rheumatology, 2011, 50, 1976-1981.	1.9	27
50	An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis. Journal of Rheumatology, 2017, 44, 1453-1457.	2.0	25
51	A comprehensive framework for navigating patient care in systemic sclerosis: A global response to the need for improving the practice of diagnostic and preventive strategies in SSc. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101707.	3.3	22
52	Patients with Systemic Sclerosis/polymyositis Overlap Have a Worse Survival Rate Than Patients Without It. Journal of Rheumatology, 2016, 43, 1838-1843.	2.0	21
53	A randomised placebo-controlled double-blind trial to assess the safety of intramuscular administration of allogeneic mesenchymal stromal cells for digital ulcers in systemic sclerosis: the MANUS Trial protocol. BMJ Open, 2018, 8, e020479.	1.9	21
54	Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the DETECT cohort. Annals of the Rheumatic Diseases, 2018, 77, 128-132.	0.9	20

#	Article	IF	Citations
55	Reporting items for capillaroscopy in clinical research on musculoskeletal diseases: a systematic review and international Delphi consensus. Rheumatology, 2021, 60, 1410-1418.	1.9	20
56	Feasibility of online home spirometry in systemic sclerosisâ€“associated interstitial lung disease: a pilot study. Rheumatology, 2021, 60, 2467-2471.	1.9	19
57	Natural variability in the disease course of SSc-ILD: implications for treatment. European Respiratory Review, 2021, 30, 200340.	7.1	18
58	Diagnostic profiles for precision medicine in systemic sclerosis; stepping forward from single biomarkers towards pathophysiological panels. Autoimmunity Reviews, 2020, 19, 102515.	5.8	17
59	Autoantibody profiles in systemic sclerosis; a comparison of diagnostic tests. Autoimmunity, 2021, 54, 148-155.	2.6	17
60	Photoacoustic and high-frequency ultrasound imaging of systemic sclerosis patients. Arthritis Research and Therapy, 2021, 23, 22.	3.5	17
61	Pharmacological treatments for SSc-ILD: Systematic review and critical appraisal of the evidence. Autoimmunity Reviews, 2021, 20, 102978.	5.8	17
62	Blood flow in the hands of a predefined homogeneous systemic sclerosis population: the presence of digital ulcers and the improvement with bosentan. Rheumatology, 2015, 54, 262-269.	1.9	16
63	Optimal care for systemic sclerosis patients: recommendations from a patient-centered and multidisciplinary mixed-method study and working conference. Clinical Rheumatology, 2019, 38, 1007-1015.	2.2	16
64	Association of a non-synonymous functional variant of the ITGAM gene with systemic sclerosis. Annals of the Rheumatic Diseases, 2011, 70, 2050-2052.	0.9	15
65	Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function. Clinical Rheumatology, 2018, 37, 2715-2722.	2.2	15
66	Exercise in systemic sclerosis intensifies systemic inflammation and oxidative stress. Scandinavian Journal of Rheumatology, 2010, 39, 63-70.	1.1	14
67	Hit hard and early: analysing the effects of high-dose methylprednisolone on nailfold capillary changes and biomarkers in very early systemic sclerosis: study protocol for a 12-week randomised controlled trial. Trials, 2018, 19, 449.	1.6	14
68	The arachidonate 5-lipoxygenase activating protein gene polymorphism is associated with the risk of scleroderma-related interstitial lung disease: a multicentre European Scleroderma Trials and Research group (EUSTAR) study. Rheumatology, 2017, 56, 844-852.	1.9	13
69	Treatment decision-making in diffuse cutaneous systemic sclerosis: a patientâ€™s perspective. Rheumatology, 2020, 59, 2052-2061.	1.9	13
70	Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis. Rheumatology, 2022, 62, 234-242.	1.9	13
71	TGFÎ²-mediated expression of TGFÎ²-activating integrins in SSc monocytes: disturbed activation of latent TGFÎ²?. Arthritis Research and Therapy, 2020, 22, 42.	3.5	12
72	Analysis of the association between CD40 and CD40 ligand polymorphisms and systemic sclerosis. Arthritis Research and Therapy, 2012, 14, R154.	3.5	11

#	Article	IF	Citations
73	Regarding â€œTranscriptional and Cytokine Profiles IdentifyÂCXCL9 as a Biomarker of Disease Activity inÂMorpheaâ€• Journal of Investigative Dermatology, 2018, 138, 1212-1215.	0.7	11
74	How do patients with systemic sclerosis experience currently provided healthcare and how should we measure its quality?. Rheumatology, 2020, 59, 1226-1232.	1.9	11
75	A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: the UPSIDE study protocol. BMJ Open, 2021, 11, e044483.	1.9	11
76	KCNA5 gene is not confirmed as a systemic sclerosis-related pulmonary arterial hypertension genetic susceptibility factor. Arthritis Research and Therapy, 2012, 14, R273.	3.5	10
77	Identifying unmet needs in SSc-ILD by semi-qualitative in-depth interviews. Rheumatology, 2021, 60, 5601-5609.	1.9	10
78	The -2518A>G promoter polymorphism in the CCL2 gene is not associated with systemic sclerosis susceptibility or phenotype: Results from a multicenter study of European Caucasian patients. Human Immunology, 2009, 70, 130-133.	2.4	9
79	Functional Variants of Fc Gamma Receptor (FCGR2A) and FCGR3A Are Not Associated with Susceptibility to Systemic Sclerosis in a Large European Study (EUSTAR). Journal of Rheumatology, 2010, 37, 1673-1679.	2.0	9
80	An easy prediction rule for diffuse cutaneous systemic sclerosis using only the timing and type of first symptoms and auto-antibodies: derivation and validation. Rheumatology, 2016, 55, 2023-2032.	1.9	9
81	Change of the microvascularization in systemic sclerosis, a matter of air. Best Practice and Research in Clinical Rheumatology, 2021, 35, 101683.	3.3	9
82	Fibroblast Activation Protein Targeted Photodynamic Therapy Selectively Kills Activated Skin Fibroblasts from Systemic Sclerosis Patients and Prevents Tissue Contraction. International Journal of Molecular Sciences, 2021, 22, 12681.	4.1	9
83	Polymorphisms in the Interleukin 4, Interleukin 13, and Corresponding Receptor Genes Are Not Associated with Systemic Sclerosis and Do Not Influence Gene Expression. Journal of Rheumatology, 2012, 39, 112-118.	2.0	8
84	Prediction of organ involvement and survival in systemic sclerosis patients in the first 5â€‰years from diagnosis. Journal of Scleroderma and Related Disorders, 2020, 5, 57-65.	1.7	8
85	Treatment with cyclophosphamide i.v. pulse therapy is an option for effective treatment of skin fibrosis in patients with early systemic sclerosis. Rheumatology, 2020, 59, 1550-1555.	1.9	8
86	Social Support, Disease-Related Cognitions and Coping as Predictors of Depressed Mood in Systemic Sclerosis. Cognitive Therapy and Research, 2008, 32, 434-447.	1.9	7
87	Chronic Q fever associated with systemic sclerosis. European Journal of Clinical Investigation, 2019, 49, e13123.	3.4	7
88	Room for improvement in non-pharmacological systemic sclerosis care? â€” a cross-sectional online survey of 650 patients. BMC Rheumatology, 2020, 4, 43.	1.6	7
89	Evidence and consensus-based recommendations for non-pharmacological treatment of fatigue, hand function loss, Raynaudâ€™s phenomenon and digital ulcers in patients with systemic sclerosis. Rheumatology, 2022, 61, 1476-1486.	1.9	7
90	Pulmonary arterial hypertension, a novelty in idiopathic inflammatory myopathies: insights and first experiences with vasoactive therapy. RMD Open, 2017, 3, e000331.	3.8	6

#	Article	IF	Citations
91	What moves the rheumatologist? Unravelling decision making in the referral of systemic sclerosis patients to health professionals: a qualitative study. Rheumatology Advances in Practice, 2018, 2, rky027.	0.7	6
92	Is there still a role for cyclophosphamide in the treatment of systemic sclerosis?. Journal of Scleroderma and Related Disorders, 2021, 6, 117-122.	1.7	6
93	Intestinal hypomotility in systemic sclerosis: a histological study into the sequence of events. Clinical Rheumatology, 2021, 40, 981-990.	2.2	6
94	Ultrasound: A Potential Tool for Detecting of Fasciitis in Dermatomyositis and Polymyositis. Journal of Rheumatology, 2018, 45, 441.1-442.	2.0	5
95	POS0054â€…THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS PATIENTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR). Annals of the Rheumatic Diseases, 2021, 80, 232.2-233.	0.9	5
96	Representativeness of systemic sclerosis patients in interventional randomized trials: an analysis of the EUSTAR database. Rheumatology, 2022, 61, 743-755.	1.9	5
97	OP0266â€…EFFICACY OF NINTEDANIB IN PATIENTS WITH SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD) AND INTERNAL ORGAN INVOLVEMENT: DATA FROM THE SENSCIS TRIAL. Annals of the Rheumatic Diseases, 2021, 80, 162.1-162.	0.9	5
98	Autologous Hematopoietic Stem Cell Transplantation Versus Intravenous Pulse Therapy Cyclophosphamide for Severe or Rapidly Progressive Systemic Sclerosis, the Astis Trial. Blood, 2012, 120, 964-964.	1.4	5
99	The Prognostic Value of Right Atrial and Right Ventricular Functional Parameters in Systemic Sclerosis. Frontiers in Cardiovascular Medicine, 2022, 9, 845359.	2.4	5
100	The Functional Polymorphism 844 A>G in FcÎ±RI (CD89) Does Not Contribute to Systemic Sclerosis or Rheumatoid Arthritis Susceptibility. Journal of Rheumatology, 2011, 38, 446-449.	2.0	4
101	Muscle ultrasonography is a potential tool for detecting fasciitis in dermatomyositis and polymyositis: comment on the article by Yoshida etÂal. Arthritis and Rheumatology, 2017, 69, 2248-2249.	5.6	4
102	Confirmation of CCR6 as a risk factor for anti-topoisomerase I antibodies in systemic sclerosis. Clinical and Experimental Rheumatology, 2015, 33, S31-5.	0.8	4
103	E070â€ƒShared decision-making in progressive diffuse cutaneous systemic sclerosis: a patientâ€™s perspective. Rheumatology, 2019, 58, .	1.9	3
104	Living with systemic sclerosis: exploring its impact on caregivers. Disability and Rehabilitation, 2020, 42, 1632-1633.	1.8	3
105	A Drugâ€“Drug Interaction Study to Investigate the Effect of Nintedanib on the Pharmacokinetics of Microgynon (Ethinylestradiol and Levonorgestrel) in Female Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. European Journal of Drug Metabolism and Pharmacokinetics, 2022, 47, 81-89.	1.6	3
106	Evaluation of Left Cardiac Chamber Function with Cardiac Magnetic Resonance and Association with Outcome in Patients with Systemic Sclerosis. Rheumatology, 2022, , .	1.9	3
107	What does the clinician need to improve patient care in systemic sclerosis?. Annals of the Rheumatic Diseases, 2007, 66, 1129-1131.	0.9	2
108	SAT0641-HPRâ€…Three-Year Trajectories of Disability and Fatigue in Systemic Sclerosis: A Cohort Study. Annals of the Rheumatic Diseases, 2015, 74, 1335.3-1335.	0.9	2

#	Article	IF	Citations
109	From â€œbeing at warâ€•to â€œgetting back on your feetâ€• A qualitative study on experiences of patients with systemic sclerosis treated with hematopoietic stem cell transplantation. Journal of Scleroderma and Related Disorders, 2020, 5, 202-209.	1.7	2
110	Selexipag treatment in patients with systemic sclerosisâ€“associated pulmonary arterial hypertension in clinical practice, a case series. Journal of Scleroderma and Related Disorders, 2020, 5, NP7-NP11.	1.7	2
111	Physical Therapy in Systemic Sclerosis: The Patient Perspective. Arthritis Care and Research, 2023, 75, 145-151.	3.4	2
112	Physical therapy in patients with systemic sclerosis: physical therapistsâ€™ perspectives on current delivery and educational needs. Scandinavian Journal of Rheumatology, 2021, , 1-8.	1.1	2
113	Opening the black box of non-pharmacological care in systemic sclerosis: a cross-sectional online survey of Dutch health professionals. Rheumatology International, 2021, 41, 1299-1310.	3.0	2
114	Three-year trajectories of disability and fatigue in systemic sclerosis: a cohort study. Clinical and Experimental Rheumatology, 2017, 35 Suppl 106, 48-55.	0.8	2
115	AB0727â€…There is a Need for New Systemic Sclerosis Subset Criteria. A Content Analytic Approach. Annals of the Rheumatic Diseases, 2015, 74, 1141.2-1141.	0.9	1
116	FRI0261â€…Observational Study of Outcome in Patients with Early Diffuse Cutaneous Systemic Sclerosis Treated with Immunosuppressive Therapies (ESOS Study). Annals of the Rheumatic Diseases, 2016, 75, 528.2-529.	0.9	1
117	Requirements for systemic sclerosis expert centres in the Netherlands: A Delphi consensus study. Journal of Scleroderma and Related Disorders, 2021, 6, 96-101.	1.7	1
118	Continued Treatment with Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Data from the SENSCIS-ON Trial. , 2021, , .		1
119	High-frequency photoacoustic and ultrasound imaging of systemic sclerosis patients. , 2019, , .		1
120	AB0582â€…DIAGNOSING SYSTEMIC SCLEROSIS WITH PHOTOACOUSTIC AND HIGH-FREQUENCY ULTRASOUND IMAGING. Annals of the Rheumatic Diseases, 2020, 79, 1588.1-1588.	0.9	1
121	FRI0248â€…Effects of bosentan in a homogeneous population of SSC subjects with a predefined restriction of blood flow in the hands (home): Preliminary results. Annals of the Rheumatic Diseases, 2013, 71, 398.1-398.	0.9	0
122	THU0247â€…Home: The effect of systemic sclerosis on the blood flow in the hands. Annals of the Rheumatic Diseases, 2013, 71, 238.2-238.	0.9	0
123	AB0217â€…Plasma Levels of Candidate Soluble Biomarkers of Disease Activity in Early Systemic Sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 964.1-964.	0.9	0
124	SAT0437â€…Occurrence of Organ Involvement in Early Systemic Sclerosis. Annals of the Rheumatic Diseases, 2015, 74, 818.1-818.	0.9	0
125	AB0650â€…Survival and Organ Involvement in Patients with Limited Cutaneous Systemic Sclerosis and Anti-Topoisomerase Antibodies. Annals of the Rheumatic Diseases, 2016, 75, 1126.3-1127.	0.9	0
126	SAT0196â€…Impress 2 (International Multicentric Prospective Study on Pregnancy in Systemic Sclerosis). Prospective, Case-Control Study of Pregnancy in Systemic Sclerosis. Annals of the Rheumatic Diseases, 2016, 75, 739.1-739.	0.9	0

#	Article	IF	Citations
127	FRI0254â€...The Effect of Cyclophosphamide on Lung Function in Different Stages of Interstitial Lung Disease Associated To Systemic Sclerosis: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 526.1-526.	0.9	0
128	OP0034â€...Factors associated with disease progression in early-diagnosed pulmonary arterial hypertension associated with systemic sclerosis: longitudinal data from the detect cohort. , 2017, , .		0
129	AB0669â€...The eular systemic sclerosis impact of disease (SCLEROID) score â€“ a new patient-reported outcome measure for patients with systemic sclerosis â€“ preliminary results from the ongoing validation study. , 2017, , .		0
130	AB0003â€...A mif promoter polymorphism is associated with the susceptibility to pulmonary arterial hypertension in diffuse cutaneous systemic sclerosis patients. , 2017, , .		0
131	AB0651â€...The effect of cyclophosphamide on pulmonary function and dependence on disease activity of interstitial lung disease associated with systemic sclerosis. , 2017, , .		0
132	AB0178â€...Phenotyping of natural killer (NK) receptors on NK and NKT-LIKE cells discloses defective immune-regulatory capability in patients with systemic sclerosis. , 2017, , .		0
133	056.â€ƒCHARACTERISTICS BY AUTOANTIBODY STATUS IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS: THE EUROPEAN SCLERODERMA OBSERVATIONAL STUDY COHORT. Rheumatology, 2017, 56, .	1.9	0
134	Pulmonary Hypertension in Systemic Sclerosis. , 2017, , .		0
135	OP0123â€...Prediction of progressive skin thickening in early diffuse systemic sclerosis using three-monthly skin scores from the european scleroderma observational study (ESOS). , 2017, , .		0
136	THU0764-HPRâ€...What moves the rheumatologist? unravelling decision making in ssc referral â€“ a qualitative study. , 2017, , .		0
137	P076â€...A bioassay to measure tgfî² activity reveals decreased tgfî² activity in systemic sclerosis serum. , 2018, , .		0
138	Treatment of Diffuse Cutaneous Systemic Sclerosis with Biologics, Small Molecules and Stem Cell Transplantation: What Is the Evidence to Date?. Current Treatment Options in Rheumatology, 2019, 5, 104-114.	1.4	0
139	SAT0259â€...PREDICTIVE FACTORS FOR TREATMENT RELATED MORTALITY AND MAJOR ADVERSE EVENTS AFTER AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SYSTEMIC SCLEROSIS: RESULTS OF A LONG TERM FOLLOW-UP MULTI-CENTRE STUDY. , 2019, , .		0
140	AB0650â€...PERSPECTIVES AND UNMET NEEDS OF PATIENTS WITH POOR PROGNOSIS SYSTEMIC SCLEROSIS ON AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION CARE: A QUALITATIVE STUDY. , 2019, , .		0
141	SAT0282â€...EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSIONIN DAILY CLINICAL PRACTICE, A CASE SERIES. , 2019, , .		0
142	OP0079â€...HPR NON-PHARMACOLOGICAL CARE IN SYSTEMIC SCLEROSIS: OPENING THE BLACK BOX. , 2019, , .		0
143	PARE0019â€...LIVING WITH SYSTEMIC SCLEROSIS: EXPLORING ITS IMPACT ON CAREGIVERS: A QUALITATIVE STUDY. , 2019, , .		0
144	AB0441â€...NAILFOLDCAPILLAROSCOPY AND CANDIDATE BIOMARKER LEVELS IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY HYPERTENSION; PROFILING OF NON-INVASIVE MARKERS, A COHORT STUDY. Annals of the Rheumatic Diseases, 2021, 80, 1248.3-1249.	0.9	0

#	Article	IF	Citations
145	FRI0437â€…Is extended auto antibody profiling associated with the prevalence of disease complications?. , 2018, , .		0
146	THU0719-HPRâ€…Non-pharmacological care in systemic sclerosis: room for improvement?. , 2018, , .		0
147	SAT0485â€…What is the effect of cyclophosphamide iv pulse therapy in patients with diffuse cutaneous systemic sclerosis on skin involvement: an observational study. , 2018, , .		0
148	AB0776â€…Muscle ultrasonography: a potential new diagnostic tool for inflammatory myopathies. , 2018, , .		0
149	THU0655â€…Patientsâ€™ evaluation of dutch health care in systemic sclerosis: unmet needs and preferences. , 2018, , .		0
150	AB0053â€…A bioassay to measure tgfÎ² activity reveals decreased tgfÎ² activity in ssc serum. , 2018, , .		0
151	AB0787â€…The eular systemic sclerosis impact of disease (SCLEROID) score â€“ a new patient-reported outcome measure for patients with systemic sclerosis. , 2018, , .		0
152	Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use*. Pneumologie, 2020, 74, .	0.1	0
153	SAT0313â€…CORRELATION BETWEEN PROGRESSION OF SKIN FIBROSIS AND PROGRESSION OF INTERSTITIAL LUNG DISEASE (ILD) IN PATIENTS WITH SSC-ILD: DATA FROM THE SENSCIS TRIAL. Annals of the Rheumatic Diseases, 2020, 79, 1101.2-1102.	0.9	0
154	The role of the NLRP1 gene in systemic sclerosis: a replication study. Clinical and Experimental Rheumatology, 2013, 31, 187-8.	0.8	0
155	Heme oxygenase-1 promoter polymorphisms do not influence susceptibility to systemic sclerosis and its clinical phenotypes. Clinical and Experimental Rheumatology, 2013, 31, 186.	0.8	0